相似文献
1
Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices.
Clinics (Sao Paulo). 2012 Nov;67(11):1349. doi: 10.6061/clinics/2012(11)22.
2
Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.
Clinics (Sao Paulo). 2012;67(5):419-24. doi: 10.6061/clinics/2012(05)03.
3
Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients.
Oncol Rep. 2013 Sep;30(3):1045-52. doi: 10.3892/or.2013.2579. Epub 2013 Jul 1.
4
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
Br J Cancer. 2008 Sep 16;99(6):923-9. doi: 10.1038/sj.bjc.6604629.
5
Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Int J Clin Exp Pathol. 2013 Aug 15;6(9):1880-9. eCollection 2013.
6
Lung cancer with translocation in the anaplastic lymphoma kinase gene: a disease within a disease.
Cancer. 2012 Sep 15;118(18):4370-1. doi: 10.1002/cncr.27402. Epub 2012 Jan 26.
7
Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer.
J Thorac Oncol. 2010 Dec;5(12):1887-93. doi: 10.1097/JTO.0b013e3181f77a53.
8
Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
BMC Res Notes. 2013 Nov 26;6:489. doi: 10.1186/1756-0500-6-489.
9
Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer.
Br J Cancer. 2014 Nov 25;111(11):2203-4. doi: 10.1038/bjc.2014.401. Epub 2014 Aug 12.
10
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Ann Oncol. 2013 Sep;24(9):2364-70. doi: 10.1093/annonc/mdt220. Epub 2013 Jun 19.
引用本文的文献
1
Mutation Testing: Changing Patterns of Molecular Testing in Brazil.
Oncologist. 2019 Apr;24(4):e137-e141. doi: 10.1634/theoncologist.2018-0254. Epub 2018 Nov 16.
2
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
PLoS One. 2014 Feb 6;9(2):e86697. doi: 10.1371/journal.pone.0086697. eCollection 2014.
3
The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the risk and prognosis of portuguese patients with non-small cell lung cancer.
PLoS One. 2013 Sep 6;8(9):e72373. doi: 10.1371/journal.pone.0072373. eCollection 2013.
本文引用的文献
1
EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study.
Tumour Biol. 2012 Dec;33(6):2061-8. doi: 10.1007/s13277-012-0465-5. Epub 2012 Jul 29.
2
Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.
Clinics (Sao Paulo). 2012;67(5):419-24. doi: 10.6061/clinics/2012(05)03.
3
Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies.
World J Clin Oncol. 2011 Nov 10;2(11):367-76. doi: 10.5306/wjco.v2.i11.367.
4
Screening for epidermal growth factor receptor mutations in lung cancer.
N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19.
5
Frequency of and variables associated with the EGFR mutation and its subtypes.
Int J Cancer. 2010 Feb 1;126(3):651-5. doi: 10.1002/ijc.24746.
6
Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
J Thorac Oncol. 2009 Jan;4(1):22-9. doi: 10.1097/JTO.0b013e3181914111.
Zotero 插件